

Fig.1

10 20 30 40 50
AUCACUCUCUUUAAUCACUACUCACAGUAACCUCUACUCCUGCCACAAUGUACAGGAU

70 80 90 100 110
AACUCCUGUCUUGCAUUGCACUAAGUCUUGCACUUGUCACAAACAGUGCACCUCUUC,
ACGTGATT CAGAACG TGAACAGTGT TTTGTC
77-91 92-106

130 140 150 160 170
GUUCUACAAAGAAAACACAGCUACAACUGGAGCAUUUACUGCUGGAUUUACAGAUGAU

190 200 210 220 230
UGAAUGGAAUUAUAAUUAACAAGAAUCCCAAACUCACCAGGAUGCUCACAUUUAAGUU
ATGTTCTTAGGGTTT GAGTGGTCCTACGAGTGTAAATTCAA
198-212 213-227 228-242

250 260 270 280 290
ACAUGCCCAAGAAGGCCACAGAACUGAAACAUCUUCAGUGUCUAGAAGAAGAACUCA
TGTACGGGTTCTTCCGG TCTTCTTGAGTT
243-257 287-301

310 320 330 340 350
CUCUGGAGGAAGUGCUAAAUUUAGCUCAAAGCAAAAACUUUCACUUAAGACCCAGGGA
GAGACCTCCTTCACGA GTGAATTCTGGGTCCCT
302-316 342-356

370 380 390 400 410
UAAUCAGCAAUAUCAACGUAAUAGUUCUGGAACUAAAGGGAUCUGAAACAACAUUCAU
ATTAGTCGTTA
357-371

430 440 450 460 470
GUGAAUAUGCUGAUGAGACAGCAACCAUUGUAGAAUUUCUGAACAGAUGGAUUACCUU

490 500 510 520 530
GUCAAAGCAUCAUCUCAACACUAACUUGAUAAUUAAGUGCUUCCACUUAACAUAUC

550 560 570 580 590 600
GGCCUUCUAUUUAUUUAAAUUUUAAAUUUUAUUAUUUAUUGUUGAAUGUAUGGUUUGCUA

610 620 630 640 650 660
CCUAUUGUAAACUAUUUAUCUUAACUUAACUUAUAAUAUGGAUCUUUUAUGAUUCUUL

670 680 690 700 710 720
UUGUAAGCCCUAGGGGCUCUAAAUGGUUUCACUUAUUUAUCCCAAUAUUUAUUUAUU

730 740 750 760 770 780
UGUUGAAUGUUAUAUAUAGUAUCUAUGUAGAUUGGUUAGUAAAACUAUUUAUAUAUUU

790 800
AUAAAUAUAAAAAAAC

Fig.2

10 20 30 40 50 60
GAUCGUUAGCUUCUCCUGAUAAACUAAUUGCCUCACAUUGUCACUGCAAUUCGACACCUA

70 80 90 100 110 120
UAAUUGGGUCUACCUCCCAACUGCUUCCCCUCUGUUCUUCUGCUAGCAUGUGCCGGC
GAGTGGAGGGTTGAC GAAGGGGGAGACAAG CG

70-84 85-99

130 140 150 160 170 180
AACUUUGUCCACGGACACAAGUGCGAUUACCUUACAGGAGAUCAUAAAACUUUGAAC
TTGAAACAGGTGC CTGTGTTACGCTAT ACTTG

119-133 134-148

190 200 210 220 230 240
AGCCUCACAGAGCAGAAGACUCUGUGCACCGAGUUGACCGUAACAGACAUCUUUGCUGCC
TCGGAGTGTC TCGTCTTCTGAGACA

176-190 191-205

250 260 270 280 290 300
UCCAAGAACACAACUGAGAAGGAAACCUUCUGCAGGGCUGCGACUGUGCUCCGGCAGUUC
TGGAAGACGTCCCGA CGCTGACACGAGGCC

265-279 280-294

310 320 330 340 350 360
UACAGCCACCAUGAGAAGGACACUCGCUGCCUGGGUGCGACUGCACAGCAGUUCCACAGG

370 380 390 400 410 420
CACAAGCAGCUGAUCCGAUUCUGAAACGGCUCGACAGGAACCUCUGGGGCCUGGCGGGC
GCTAAGGACTTTGCC GAGCTGTCCTTGGAG

376-390 391-405

430 440 450 460 470 480
UUGAAUUCUGUCCUGUGAAGGAAGCCAACCAGAGUACGUUGGAAAACUUCUUGGAAAG

490 500 510 520 530 540
CUAAAGACGAUCAUGAGAGAGAAUAUUAAGUGUUCGAGCUGAAUAUUUUAAUUUAUG

550 560 570 580 590 600
AGUUUUUGAUAGCUUUUUUUUAAGUAUUUAUUAUUUAACUCAUAAAAUAAAG

610
UAUAUAUAGAAUCUAAAA

Fig.3




Fig.4




Fig.5




Fig.6




Fig.7




Fig.8




Fig.9




Fig.10




Fig.11




Fig.12




Fig.13

IL-2 342-356




Fig.14

IL-2 357-371




Fig.15

IL-4 119-133




Fig.16

IL-4 134-148




Fig.17

IL-4 265-279




Fig.18

IL-4 280-294





Fig.19



¹ Time after adding 10 nM PMA, 0.5 mg/ml anti-human CD3 antibody and anti-human CD28 antibody to cultured Jurkat E6-1 cells

² The concentration of IL-2 in the culture supernatants measured by ELISA using anti-human IL-2 antibody

³ ⁴ Determination of cellular IL-2 expression level by dot blotting using RNA probe complementary to human IL-2 mRNA

Fig. 20

DIG-11-dUTP & Reverse transcriptase	Oligonucleotide	IL-2 expression	
		(+)	(-)
none	none		
none	none		
added	oligo dA		
added	oligo dT		

Fig. 21

PROBE	IL-2 EXPRESSION		
	(+)	(-)	
IL-2 228-242(D)			
IL-2 243-257(A)			
IL-2 198-212(D)			
IL-2 213-227(A)			
IL-2 77-91(D)			
IL-2 92-106(A)			
IL-2 287-301(D)			
IL-2 302-316(A)			
IL-2 342-356(D)			
IL-2 357-371(A)			
NONE			

Fig.22




Fig. 23

PROBE	IL-2 EXPRESSION					
	(+)			(-)		
IL-2 228-242(D) & IL-2 243-257(A)	D/A	A/A	D/D	D/A	A/A	D/D
IL-2 198-212(D) & IL-2 213-227(A)						
IL-2 77-91(D) & IL-2 92-106(A)						
IL-2 287-301(D) & IL-2 302-316(A)						
IL-2 342-356(D) & IL-2 357-371(A)						
NONE & NONE						

Fig. 24




Fig.25




Fig.26





Fig.27



Title: Method For Selectively Separating Live Cells Expressing A Specific Gene

Inventors: ISHIBASHI et al.

Atty Docket No.: 400684/SOEI

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.28




Fig.29




Fig.30




Fig.31




Fig.32




Fig.33




Fig.34




Fig.35




Fig.36




Fig.37




Fig.38




Fig.39




Fig.40





Fig.41



Title: Method For Selectively Separating Live Cells Expressing A Specific Gene

Inventors: ISHIBASHI et al.

Atty Docket No.: 400684/SOEI

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.42




Fig.43




Fig.44




Fig.45





Fig.46



Title: Method For Selectively Separating Live Cells Expressing A Specific Gene

Inventors: ISHIBASHI et al.

Atty Docket No.: 400684/SOEI

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.47

IL-2 mRNA (+); 48/48

400684-10000

Title: Method For Selectively Separating Live Cells Expressing A Specific Gene

Inventors: ISHIBASHI et al.

Atty Docket No.: 400684/SOEI

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.48

IL-2 mRNA (+); 9/9



FIG. 48

Fig. 49

IL-2 mRNA (+); 0/32

[illegible]

Title: Method For Selectively Separating Live Cells Expressing A Specific Gene

Inventors: ISHIBASHI et al.

Atty Docket No.: 400684/SOEI

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.50

IL-2 mRNA (+); 18/35

Title: Method For Selectively Separating Live Cells Expressing A Specific Gene

Inventors: ISHIBASHI et al.

Atty Docket No.: 400684/SOEI

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.51

IL-2 mRNA (+); 7/7



Fig.52

IL-2 mRNA (+); 8/39



Fig.53

IL-2 mRNA (+); 8/8



Fig.54




Fig.55




Fig.56




Fig.57




Fig.58




Fig.59




Fig.60




Fig.61




Fig.62




Fig.63




Fig.64




Fig.65




Fig.66




Fig.67




Fig.68




Fig.69




Fig.70




Fig.71




Fig.72




Fig.73




Fig.74




Fig.75




Fig.76




Fig.77




Fig.78




Fig.79




Fig.80




Fig.81




Fig.82




Fig.83




Fig.84




Fig.85




Fig.86

IL-2 mRNA (+); 5/24

IL-4 mRNA (+); 3/43

Fig. 87

IL-2 mRNA (+); 11/11	γ -IF mRNA (+); 14/14	TNF- β mRNA (+); 11/11
IL-4 mRNA (+); 0/10	IL-5 mRNA (+); 0/11	IL-10 mRNA (+); 0/9

Fig.88




FIG. 89

Fig. 89

IL-2 mRNA (+); 0/11	γ -IF mRNA (+); 0/11	TNF- β mRNA (+); 0/9
IL-4 mRNA (+); 12/12	IL-5 mRNA (+); 11/11	IL-10 mRNA (+); 11/11

Fig.90




Fig. 91

IL-2 mRNA (+); 10/10	γ -IF mRNA (+); 9/9	TNF- β mRNA (+); 9/9
IL-4 mRNA (+); 0/9	IL-5 mRNA (+); 0/8	IL-10 mRNA (+); 0/9

Fig.92




FIG. 93

Fig. 93

IL-2 mRNA (+); 0/7	γ -IF mRNA (+); 0/8	TNF- β mRNA (+); 0/8
IL-4 mRNA (+); 9/9	IL-5 mRNA (+); 10/10	IL-10 mRNA (+); 9/9

Fig.94

